Healthcare / Drug Manufacturers - GeneralTokyo
$152.00
-1.00 (-0.65%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-794.6M · quality 65.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-63.2%
↓Gross Margin
86.4%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.7%
FCF CAGR
—
FCF margin
-660.1%
FCF / Net income
0.88x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $120.4M · net income $-904.8M · FCF $-794.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $120.4M | $120.4M | $100.4M | $94.2M | $71.9M |
| Net Income | $-904.8M | $-904.8M | $-1.10B | $-787.0M | $-599.0M |
| EBITDA | $-823.6M | $-823.6M | $-891.2M | $-692.1M | $-469.2M |
| EPS | -63.41 | -63.41 | -93.69 | -66.93 | -54.47 |
| Gross Margin | 86.4% | 86.4% | 87.3% | 91.9% | 94.2% |
| Operating Margin | -686.5% | -686.5% | -891.1% | -740.7% | -656.4% |
| Net Margin | -751.7% | -751.7% | -1100.0% | -835.4% | -832.8% |
| Balance Sheet | |||||
| Current Ratio | 24.74 | 24.74 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-794.6M | $-794.6M | $-992.9M | $-734.8M | $-510.7M |
| Returns | |||||
| ROE | -63.2% | -63.2% | -79.0% | -32.8% | -19.0% |
| Valuation | |||||
| P/B | 1.51 | 1.51 | 2.64 | 1.45 | 1.40 |
| Growth & Yield | |||||
| Revenue Growth | 19.9% | 19.9% | 6.6% | 31.0% | — |
| EPS Growth | 32.3% | 32.3% | -40.0% | -22.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-65.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-93.69 → -63.41
Residual
-65.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.